CJC-1295 (With DAC)

CJC-1295 (With DAC)

CJC-1295 (With DAC) is a long-acting synthetic analogue of growth hormone-releasing hormone (GHRH), engineered with a Drug Affinity Complex (DAC) technology that enables covalent binding to serum albumin. This albumin conjugation dramatically extends the peptide's half-life to approximately 6–8 days, enabling sustained, non-pulsatile elevation of growth hormone levels in research models. It is used in preclinical studies investigating chronic GH/IGF-1 axis stimulation and its downstream metabolic and anabolic effects.

Mechanism of Action

CJC-1295 (With DAC) binds to the GHRH receptor on pituitary somatotrophs, stimulating GH synthesis and secretion. The DAC moiety — a maleimidopropionic acid linker — reacts with the free thiol group of Cys34 on serum albumin, forming a stable covalent bond that protects the peptide from enzymatic degradation and renal clearance. This results in a prolonged GH release profile distinct from the pulsatile pattern of the No DAC variant, making it a useful tool for studying the differential effects of tonic versus pulsatile GH secretion.

Research Applications

• Chronic GH/IGF-1 axis stimulation and sustained anabolic signalling studies
• Albumin-binding drug delivery and pharmacokinetic research
• Pulsatile vs. tonic GH secretion comparison modelling
• Body composition, lipolysis, and metabolic regulation investigation
• GHRH receptor pharmacology and long-acting peptide studies

Specifications

• Molecular Formula: C₁₆₅H₂₆₉N₄₇O₄₆
• CAS Number: 863288-34-0
• Purity: ≥98%
• Molecular Weight: 3647.3 g/mol
• Form: Lyophilised powder
• Storage: -20°C
• Shelf Life: 24 months

This product is intended for legitimate laboratory and analytical research use only. Not for diagnostic, therapeutic, or consumer use.